Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RAPP vs SION: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RAPP Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–2 Matrix Metrics)

RAPP Overall Winner 6-Pillar Tally: RAPP 3 – 2 SION (1 Tie) Matrix Metrics: RAPP 4 – 2 SION

As of Nov 16, 2026, Rapport Therapeutics, Inc. (RAPP) is the stronger overall head-to-head candidate over Sionna Therapeutics, Inc. (SION) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). RAPP carries a Unified Composite Score of 51.4/100 (HOLD) at $24.82 (N/M Forward P/E, -838.1% operating margin), whereas SION carries 45.6/100 (HOLD) at $3.12 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: RAPP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.4); meanwhile SION is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RAPP vs SION
RAPP NASDAQ Head-to-Head Winner
Rapport Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$24.82
-5.09% 1D
Market Cap $1.6B
TTM Revenue $20M
Forward P/E N/M
Beta / 30D Vol 1.31β · 108% Vol
Unified Composite Score
51.4 / 100 HOLD
Tech 62.0 Fund 63.0 Flow 68.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.6%), weak momentum, RSI 42
RSI-14: 42.4 · SMA20: $25.63 · SMA50: $31.52
SION NASDAQ
Sionna Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.12
-6.31% 1D
Market Cap $150.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.97β · 78% Vol
Unified Composite Score
45.6 / 100 HOLD
Tech 34.0 Fund 50.0 Flow 67.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.6%), weak momentum, RSI 32
RSI-14: 31.9 · SMA20: $3.67 · SMA50: $4.84

6-Pillar Scorecard Institutional Category Breakdown (RAPP 3 – 2 SION)

Columns: Metric · RAPP · SION
1. Valuation Multiples RAPP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 74.2x N/M
2. Growth & Scale RAPP
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $20M N/A
Market Cap $1.6B $150.6M
3. Profitability & Quality SION
Gross Margin N/A N/A
Operating Margin -838.1% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -33.3% -39.0%
4. Balance Sheet & Cash Flow SION
Cash Generation (TTM) -$121M -$80M
Cash Flow Margin N/A N/A
Net Cash / Leverage $65M Net Cash $76M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RAPP
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 91.1% (6th %ile) 87.7% (10th %ile)
Put/Call OI Skew 0.91x (Balanced) 93.27x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RAPP (4) vs SION (2)
Institutional Metric RAPP SION Criterion Row Edge
Market Capitalization
Scale
$1.6B $150.6M Larger Scale RAPP
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
-838.1% 0.0% Higher Margin SION
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-33.3% -39.0% Higher ROE RAPP
52-Week Range Position
Momentum
9% ($22–$53) 0% ($3–$55) Stronger Trend RAPP
Beta / 30D Volatility
Risk Regime
1.31β · 108% Vol 1.97β · 78% Vol Lower Realized Risk SION
Unified Institutional Score
Composite Signal
51.4 / 100 (HOLD) 45.6 / 100 (HOLD) Higher Composite RAPP
Trailing 12M Revenue (USD)
Operating Scale
$20M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 74.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$121M ($65M Net Cash) -$80M ($76M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RAPP +9.82 pp
RAPP: -9.97% · SION: -19.79%
3M Horizon SION +1.89 pp
RAPP: -49.36% · SION: -47.47%
6M Horizon RAPP +62.6 pp
RAPP: -29.45% · SION: -92.05%
1Y Horizon RAPP +91.91 pp
RAPP: +0.61% · SION: -91.3%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RAPP vs SION. Trailing 12-month operating profitability (RAPP -838.1% vs SION 0.0%) and valuation multiples (RAPP N/M vs SION N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RAPP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$20M
Gross MarginN/A
Op. Margin-838.1%
ROE / Fwd P/E-33.3% · N/M
SION ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-39.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RAPP BREAKDOWN
133d in phase · OBV NEUTRAL
Current IV 91.1%
IV Percentile 6th %ile
Put/Call OI Skew 0.91x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RAPP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SION BREAKDOWN
45d in phase · OBV ACCUMULATION
Current IV 87.7%
IV Percentile 10th %ile
Put/Call OI Skew 93.27x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SION Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RAPP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.6B market capitalization and -838.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SION Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $150.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RAPP vs SION Key Questions & Quantitative Answers

As of Nov 16, 2026, Rapport Therapeutics, Inc. (RAPP) is the stronger overall head-to-head candidate over Sionna Therapeutics, Inc. (SION) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). RAPP carries a Unified Composite Score of 51.4/100 (HOLD) at $24.82 (N/M Forward P/E, -838.1% operating margin), whereas SION carries 45.6/100 (HOLD) at $3.12 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: RAPP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.4); meanwhile SION is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RAPP leads the Growth & Scale pillar: RAPP posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $20M TTM revenue (N/A gross margin, -838.1% operating margin), compared with SION at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, RAPP generates $20M in USD-normalized revenue versus N/A for SION. In operating R&D and SG&A reinvestment, RAPP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SION.

RAPP screens cheaper on headline valuation multiples. RAPP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 74.2x EV/Revenue (unreported FCF margin), whereas SION trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RAPP (-33.3% ROE) versus SION (-39.0% ROE) capital efficiency.

In options market volatility and institutional positioning, RAPP carries 91.1% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.91x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.31β · 108% Vol realized risk). By comparison, SION carries 87.7% implied volatility (10th %ile, Compressed (<25th %ile)), a 93.27x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.97β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.